NASDAQ:LUNG Pulmonx (LUNG) Stock Price, News & Analysis $6.13 0.00 (0.00%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Pulmonx Stock (NASDAQ:LUNG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pulmonx alerts:Sign Up Key Stats Today's Range$5.96▼$6.1650-Day Range$5.72▼$8.5852-Week Range$5.46▼$14.84Volume208,102 shsAverage Volume404,585 shsMarket Capitalization$237.94 millionP/E RatioN/ADividend YieldN/APrice Target$14.83Consensus RatingModerate Buy Company OverviewPulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Pulmonx Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks66th Percentile Overall ScoreLUNG MarketRank™: Pulmonx scored higher than 66% of companies evaluated by MarketBeat, and ranked 352nd out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingPulmonx has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePulmonx has only been the subject of 2 research reports in the past 90 days.Read more about Pulmonx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Pulmonx are expected to grow in the coming year, from ($1.64) to ($1.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulmonx is -4.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulmonx is -4.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPulmonx has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pulmonx's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.75% of the float of Pulmonx has been sold short.Short Interest Ratio / Days to CoverPulmonx has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Pulmonx has recently decreased by 6.67%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPulmonx does not currently pay a dividend.Dividend GrowthPulmonx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.75% of the float of Pulmonx has been sold short.Short Interest Ratio / Days to CoverPulmonx has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Pulmonx has recently decreased by 6.67%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.34 News SentimentPulmonx has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Pulmonx this week, compared to 2 articles on an average week. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Pulmonx insiders have sold 271.01% more of their company's stock than they have bought. Specifically, they have bought $97,436.00 in company stock and sold $361,494.00 in company stock.Percentage Held by InsidersOnly 5.70% of the stock of Pulmonx is held by insiders.Percentage Held by Institutions91.04% of the stock of Pulmonx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pulmonx's insider trading history. Receive LUNG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter. Email Address LUNG Stock News HeadlinesInsider Selling: Pulmonx Co. (NASDAQ:LUNG) Director Sells 20,000 Shares of StockOctober 22 at 4:46 AM | insidertrades.comPulmonx to Report Third Quarter 2024 Financial Results on October 30, 2024October 16, 2024 | globenewswire.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)Wells Fargo Reaffirms Their Hold Rating on Pulmonx (LUNG)September 10, 2024 | markets.businessinsider.comPulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024September 9, 2024 | globenewswire.comAeriseal’s Market Potential and Safety Profile: Justifying a Hold Rating for PulmonxAugust 31, 2024 | markets.businessinsider.comPulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth ConferenceAugust 29, 2024 | finance.yahoo.comPulmonx to Present at the 2024 Wells Fargo Healthcare ConferenceAugust 22, 2024 | globenewswire.comSee More Headlines LUNG Stock Analysis - Frequently Asked Questions How have LUNG shares performed this year? Pulmonx's stock was trading at $12.75 at the start of the year. Since then, LUNG stock has decreased by 51.9% and is now trading at $6.13. View the best growth stocks for 2024 here. How were Pulmonx's earnings last quarter? Pulmonx Co. (NASDAQ:LUNG) issued its quarterly earnings results on Wednesday, July, 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.41) by $0.02. The business had revenue of $20.78 million for the quarter, compared to the consensus estimate of $20.23 million. Pulmonx had a negative trailing twelve-month return on equity of 50.79% and a negative net margin of 75.56%. When did Pulmonx IPO? Pulmonx (LUNG) raised $100 million in an initial public offering on Thursday, October 1st 2020. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers. Who are Pulmonx's major shareholders? Pulmonx's top institutional shareholders include SG Americas Securities LLC (0.03%) and nVerses Capital LLC (0.01%). Insiders that own company stock include Glendon E French III, Derrick Sung, Geoffrey Beran Rose, David Aaron Lehman, John Mckune, Richard Ferrari and Alissa Hsu Lynch. View institutional ownership trends. How do I buy shares of Pulmonx? Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Pulmonx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pulmonx investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX), Advanced Micro Devices (AMD) and Home Depot (HD). Company Calendar Last Earnings7/31/2024Today10/23/2024Next Earnings (Confirmed)10/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:LUNG CUSIPN/A CIK1127537 Webpulmonx.com Phone1-650-364-0400FaxN/AEmployees250Year FoundedN/APrice Target and Rating Average Stock Price Target$14.83 High Stock Price Target$17.00 Low Stock Price Target$10.00 Potential Upside/Downside+142.0%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,840,000.00 Net Margins-75.56% Pretax Margin-74.80% Return on Equity-50.79% Return on Assets-33.06% Debt Debt-to-Equity Ratio0.37 Current Ratio8.97 Quick Ratio7.92 Sales & Book Value Annual Sales$76.58 million Price / Sales3.11 Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book1.98Miscellaneous Outstanding Shares38,816,000Free Float36,921,000Market Cap$237.94 million OptionableOptionable Beta0.64 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NASDAQ:LUNG) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmonx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmonx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.